Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer, today announced that it has confirmed in an in vitro study that VERU-111 has anti-inflammatory action against the key cytokines involved in the cytokine storm triggered by the SARS-CoV-2 infection.
- August 4: Wallstreet Online
- August 4: Stockwatch